Merck KGaA posted this:Technology for Lysophosphatidic Acid (LPA) Receptor antagonistsMerck has developed and patented the results of its intense R&D activities for the identification of small organic molecules as antagonists to certain LPA receptors (LPAR1, -R2, -R3). Herein described are LPA-R2 receptor selective inhibitors. Based upon a rational screening cascade established, compounds have been identified and characterized with regard to their specific in vitro and cellular activities. The package includes access to the IP, experimental results, and materials. Merck offers the unique chance to acquire this promising program.
Merck KGaA posted this:Technology for Serum and Glucocorticoid regulated kinase (SGK) inhibitorsMerck KGaA, Darmstadt, Germany, has developed and patented the results of its intense R&D activities for the identification of small organic molecules as SGK1 inhibitors. Based upon a rational screening cascade established, compounds have been identified and characterized with regard to their specific in vitro, cellular and in vivo activities. The package includes access to the IP, experimental results, and materials. Merck KGaA, Darmstadt, Germany, offers the unique chance to acquire this promising program.
UATEC - Unidade de Transferência de Tecnologia posted this:Fluorescent compounds, methods of manufacturing and uses thereofA group of researchers from a Portuguese university developed a family of new fluorophores to be used in biological imaging, either in cells or in entire organisms, in fluorescence microscopy techniques, including live cell imaging. The fluorophores are not toxic to cells and organisms, and light up cells by binding to organelles such as the Golgi apparatus, nucleus, and particularly lipid droplets. Importantly, the fluorophores change color with the polarity of the environment. The university is looking for companies that would be interested in developing this technology further through partnership, or in commercializing the probes through licensing or acquisition of the patent.
JPT Peptide Technologies posted this:Custom Peptide SynthesisJPT Peptide Technologies has a substantial, long-standing expertise in custom peptide synthesis services, providing custom peptides with highest quality for even complex or unusual peptide sequences. If you would like to order a quality peptide synthesis service using regulated processes, choose JPT! Furthermore, our peptide synthesis service has a very high success rate (over 99%) as JPT has developed the know-how to choose and optimize the appropriate synthesis method for each peptide. We go the extra mile to get your peptides done!
IMIM Institut Recerca Hospital del Mar posted this:New method for the determination of the risk of atypical fractures in patients treated with bone remodelling inhibitors.Up to date there is not any technology for detecting the risk to suffer atypical fractures related to long-term treatment with bone remodelling inhibitors. The invention will be of usefulness for individualize treatments in patients treated with bone remodelling inhibitors by detecting the individual risk of suffering atypical fractures. The invention is planned to be included into an in-vitro diagnostic tool for the atypical fracture, which will be included into standard disease management protocols and therefore used routinely by physicians prior to and after the prescription of bone remodelling drugs and further osteoporosis drugs. Osteoporosis is a progressive bone disease with a characteristic decrease in bone mass and density which can lead to an increased risk of fracture. There are two types of osteoporosis: •Type 1: most common in women after menopause, named postmenopausal osteoporosis •Type 2: Senile osteoporosis, occurs mostly after age of 75 years and has equally effect in women and in men Based on the WHO diagnostic criteria, approximately 22 million women and 5.5 million men aged between 50 and 84 years had osteoporosis in the European Union (EU) in 2010, whilst osteoporosis can be found in the list of 10 most important diseases named by the WHO. Due to changes in population demography, the number of men and women with osteoporosis might rise from 27.5 million in 2010 to 33.9 million in 2025, corresponding to an increase of 23%. The number of new fractures in the EU in 2010 was estimated at 3,5 million cases, in between these approximately 620.000 hip fractures, 520.000 vertebral fractures, 560.000 forearm fractures and 1.800.000 fractures of i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and other femoral fractures. Two thirds of all fractures occurred in women. In 2010, the number of deaths causally related to fractures was estimated at 43.000. The corresponding cost of osteoporosis in the EU, also in 2010 figures, including pharmacological intervention, was estimated at €37 billion out of which costs of treating fractures represented 66%, pharmacological prevention 5% and long term fracture care 29%. The total health burden was estimated at 1 180 000 lost Quality Adjusted Life Years (QALY) for the EU. The total cost in the EU might rise from €98 billion in 2010 to €120 billion Euro in 2025. The use of osteoporosis drugs has increased considerably. Approved pharmacological interventions (bisphosphonates, strontium ranelate, raloxifene, denosumab and parathyroid hormone peptides) are widely available but their use is restricted by reimbursement policies. Alendronate (a bisphosphonate) is the most commonly prescribed agent, accounting for approximately a quarter of the total value of sales. The potential users/partners are pharmaceutical companies, excluding pure generic companies (lacking development resources, relevant lobbying and sales channel to the policy makers and practitioner) selling drugs in the indication osteoporosis
Research & Technology Organization
Universidad de Alcalá-OTRI posted this:Procedure for obtaining peptides with antioxidant and antihypertensive properties from olive seeds.A research group from the Analytical Chemistry Department at Alcalá University has developed a procedure from which it is possible to obtain peptides with antihypertensive and antioxidant capacity of isolated proteins from olive seed by enzymatic digestion. The method consists of the protein extraction from the olive seeds using a previously developed process, and digest the extracted proteins with Thermolysin enzyme, allowing to obtain peptides with antihypertensive capacity in vitro, or with Alcalase enzyme leading to obtain a peptide extract with antioxidant properties. The group seeks to establish commercial , licensing or collaboration agreements with companies of the food and pharmaceutical sectors interested in both the use strategy of this waste material (olive pits), as in the use of the found bioactive peptides.
Creative Biogene posted this:Human SSTR1-FLAG Stable Cell Line-CHOSomatostatin receptors (SSTRs) are activated by somatostatin secreted from nerve and endocrine cells. SSTRs are expressed in a tissue-specific manner and involved in the regulation of secretion of insulin, glucagon and growth hormone as well as cell growth induced by neuronal excitation in both the central and peripheral nervous systems.
Creative Biogene posted this:Human HTR7-FLAG Stable Cell Line-HEK293TThe 5-HT7 receptor is a member of the GPCR superfamily of cell surface receptors and is activated by the neurotransmitter serotonin. The 5-HT7 receptor is expressed in a variety of tissues, particularly in the brain, the gastrointestinal tract, and various blood vessels.
Creative Biogene posted this:Human P2RY6-FLAG Stable Cell Line-1321N1The human P2Y6 receptor is a member of the G protein-coupled P2 receptor family that responds specifically to the extracellular nucleotide uridine diphosphate (UDP). The distribution of the P2Y6 receptor is widespread including heart, blood vessels and brain. P2Y6 receptors are significantly upregulated in T cells infiltrating regions of inflamed bowel and are involved in monocytic release of IL-8 in response to UDP or lipopolysaccharide (LPS).
Small and Medium Enterprise
Creative Proteomics posted this:2,6-DIBDE (BDE-10) 50 UG/ML IN NONANE UNLABELED CERTIFIED STANDARDCreative Proteomics provides a full range of drug development services, including Molecular Biology, Biochemistry, Systems Biology, Organic Chemistry, Genomics, Bioinformatics, Structural Biology, Preclinical and Clinical studies. Please contact us to know more about 2,6-DIBDE (BDE-10) 50 UG/ML IN NONANE UNLABELED CERTIFIED STANDARD!